Stockholm, Sweden – This week, from June 27 to June 29, the International Federation of Psoriatic Associations (IFPA) convenes the 7th World Psoriasis and Psoriatic Arthritis Conference, themed “Uncovering the broad spectrum of psoriatic disease.” Hosted every three years, this year’s event gathers clinical experts, healthcare professionals, researchers, and advocacy organizations to explore the latest advancements in managing psoriasis and psoriatic arthritis.
UCB, a dedicated advocate for enhancing the lives of individuals affected by psoriasis and psoriatic arthritis, proudly supports the conference as a diamond sponsor. The company’s commitment to these immuno-dermatological conditions underscores its involvement in sharing cutting-edge research and innovations aimed at improving patient outcomes.
Psoriasis, affecting over 125 million people globally, often progresses to psoriatic arthritis in 30% of cases. This inflammatory condition can severely impact joint health and overall quality of life if not properly managed. Recognizing these challenges, UCB remains steadfast in its mission to develop effective solutions tailored to addressing the multifaceted burdens of these diseases.
At IFPA Conference 2024, UCB highlights include the presentation of seven scientific abstracts, featuring five focused on psoriasis and two on psoriatic arthritis. A significant event during the conference is UCB’s scientific symposium titled “Exploring the patients’ path: how can we raise the standard of care in psoriatic disease?” scheduled for Friday, June 28th. This symposium brings together leading opinion leaders to discuss recent developments in treatment strategies.
Delegates can also engage with UCB at their exhibition booth, where the company showcases its immuno-dermatology portfolio and offers opportunities for networking and learning.
“Collaboration and partnership are essential for advancing immuno-dermatology,” notes UCB, emphasizing its commitment to fostering connections within the scientific community and among patients. Such collaborations facilitate ongoing advancements in treatment approaches, ultimately elevating the standard of care for those affected by these conditions.
IFPA Conference 2024 promises to deliver meaningful discussions and insights centered around patient care and treatment advancements in psoriasis and psoriatic arthritis. Attendees are encouraged to connect with #TeamUCB on-site to explore opportunities for collaboration and learning.
About UCB: With a strong heritage in immunology, UCB leverages evidence-based science to deliver impactful solutions and services across the healthcare spectrum. Through data-driven innovation and rigorous scientific research, UCB aims to positively transform the lives of individuals living with psoriasis and psoriatic arthritis.
Related Topics:
